Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle(The University of Texas MD Anderson Cancer Center), Sameek Roychowdhury(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Saeed Sadeghi(University of California, Los Angeles), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Karl Heinz Weiss(Heidelberg University), Dirk‐Thomas Waldschmidt(University of Cologne), Lipika Goyal(Massachusetts General Hospital), Ivan Borbath(Cliniques Universitaires Saint-Luc), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Mitesh J. Borad(Mayo Clinic in Arizona), Wei Peng Yong(National University of Singapore), Philip A. Philip(The Barbara Ann Karmanos Cancer Institute), Michael Bitzer(University of Tübingen), S. Tanasanvimon(Chulalongkorn University), Li Ai, Amit Pande(QED Technologies (United States)), Harris S. Soifer(QED Technologies (United States)), Stacie Peacock Shepherd(QED Technologies (United States)), Susan Moran(QED Technologies (United States)), Andrew X. Zhu(Massachusetts General Hospital), Tanios Bekaii‐Saab(Mayo Clinic in Arizona), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center)
Cited by 420
Abstract
Related Papers
No related papers found
Powered by citation graph analysis